Technical Analysis for RDUS - Radius Health, Inc.

Grade Last Price % Change Price Change
grade B 21.07 -1.91% -0.41
RDUS closed down 1.91 percent on Friday, May 17, 2019, on 73 percent of normal volume. It was able to find support at its 50 day moving average.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical RDUS trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
50 DMA Support Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
20 DMA Support Bullish -1.91%
Bollinger Band Squeeze Range Contraction -1.91%
Outside Day Range Expansion -1.91%
20 DMA Support Bullish -3.66%
Bollinger Band Squeeze Range Contraction -3.66%
NR7 Range Contraction -3.66%
Crossed Above 20 DMA Bullish -1.86%

Older signals for RDUS ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Radius Health, Inc., a biopharmaceutical company, focuses on developing novel therapeutics for patients with osteoporosis and other serious endocrine-mediated diseases in the United States. Its lead product includes abaloparatide (BA058), a novel synthetic peptide analog of parathyroid hormone-related protein, which is in Phase III clinical development for the treatment of osteoporosis. The company is also developing RAD1901, a selective estrogen receptor down-regulator/degrader for the treatment of breast cancer brain metastases, and vasomotor symptoms; and RAD140, a nonsteroidal selective androgen receptor modulator, which is in preclinical development stage for the treatment of weight loss due to cancer cachexia, muscle frailty and osteoporosis, and breast cancer. It has collaborations and license agreements with Nordic Bioscience Clinical Development VII A/S; 3M; Ipsen Pharma SAS; Eisai; Lonza Group Ltd.; and Charles River Laboratories, Inc. The company was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Biopharmaceutical Cancer Drugs Breast Cancer Endocrine System Hormones Osteoporosis Amines Treatment Of Breast Cancer Antiestrogens Eisai Selective Estrogen Receptor Modulators
Is RDUS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 31.92
52 Week Low 12.81
Average Volume 577,599
200-Day Moving Average 18.7393
50-Day Moving Average 20.7144
20-Day Moving Average 21.2915
10-Day Moving Average 21.348
Average True Range 1.1274
ADX 14.76
+DI 22.6056
-DI 22.899
Chandelier Exit (Long, 3 ATRs ) 19.5678
Chandelier Exit (Short, 3 ATRs ) 22.9522
Upper Bollinger Band 22.2331
Lower Bollinger Band 20.3499
Percent B (%b) 0.38
BandWidth 8.844844
MACD Line 0.0984
MACD Signal Line 0.1621
MACD Histogram -0.0637
Fundamentals Value
Market Cap 914.11 Million
Num Shares 43.4 Million
EPS -5.19
Price-to-Earnings (P/E) Ratio -4.06
Price-to-Sales 1353.51
Price-to-Book 6.40
PEG Ratio -0.13
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 22.29
Resistance 3 (R3) 22.29 21.90 22.08
Resistance 2 (R2) 21.90 21.59 21.89 22.01
Resistance 1 (R1) 21.48 21.40 21.29 21.48 21.95
Pivot Point 21.09 21.09 20.99 21.08 21.09
Support 1 (S1) 20.67 20.78 20.48 20.67 20.19
Support 2 (S2) 20.28 20.59 20.27 20.13
Support 3 (S3) 19.86 20.28 20.06
Support 4 (S4) 19.86